TMDX Medical Technology · Medtech · Transplants · Logistics · Thesis updated July 19, 2026

Growth bet meets donor volume friction

TransMedics is trying to replace old cold storage with its Organ Care System for donor hearts, lungs, and livers.
Q1 2026 revenue was $173.9 million, up 21% year over year, but growth has slowed from earlier years.
Product revenue was $108 million and service revenue was $66 million in Q1 2026.
The National Organ Program adds a logistics moat, but aircraft and staffing make the model harder to scale.
The next test is whether CHOPS, Europe, and possible OPO bids can offset donor volume pressure and lower margins.

01 Running thesis

A bigger bet, with less cushion

TransMedics has built a rare position in transplant care. Its Organ Care System keeps donor organs warm and working outside the body, which can help transplant teams use more hearts, lungs, and livers. The company then wrapped that device business in the National Organ Program, or NOP, which handles organ retrieval and transport.

The bull case is that this becomes a hard-to-copy transplant network. Management is adding CHOPS, a cold-preservation device for short-transport hearts, building a European NOP with PAD Aviation, and preparing to bid on donor service areas tied to decommissioned U.S. organ procurement groups if regulators allow it. Kidney is another future growth option through the Gen 3.0 platform.

The bear case has become easier to see. Q1 2026 revenue grew 21% year over year, but net income fell to $7.3 million from $25.7 million a year earlier. Growth is still real, yet margins are under pressure as the company spends on Europe, new devices, aircraft, and staff. U.S. donor volumes were also below expectations because organ procurement organizations are reacting to the Transplant Modernization Act.

May 2026▼Q1 2026 revenue rose to $173.9 million, but growth slowed to 21% and net income fell to $7.3 million from $25.7 million a year earlier. The page now gives more weight to margin pressure and donor volume friction.

May 2026→Management added major growth bets with CHOPS, a European NOP plan through PAD Aviation, and possible bids for decommissioned OPO regions. These expand the opportunity, but they also add execution and capital risk.

Feb 2026→The 2025 Form 10-K showed full-year revenue of $605.5 million, up 37.1%, but growth slowed from 82.7% in 2024. The story shifted from hyper-growth to proving durable, profitable growth.

Oct 2025▲Q3 2025 results showed revenue of $143.8 million and net income of $24.3 million. Plans for an Italy facility supported the long-term OCS and disposable supply story.

Jul 2025▲Q2 2025 revenue grew to $157.4 million and net income rose to $34.9 million. The results supported the view that NOP could scale profitably.

May 2025▲Q1 2025 revenue and net income both rose sharply year over year. The update strengthened confidence in the NOP model while keeping aircraft spending as a key watch item.

Feb 2025▲The 2024 Form 10-K showed $441.5 million of revenue and the company’s first full year of profitability. Vertical integration into aviation became a core part of the thesis.

Oct 2024▲Q3 2024 results showed strong revenue growth led by NOP service revenue. The update reinforced the idea that TransMedics could change the transplant standard of care.

02 Business model

Devices plus the transplant road crew

TransMedics makes money in two main ways. First, it sells single-use disposable sets for each transplant that uses its OCS consoles. This is the razor-and-blade part of the model: the console can be reused, but the organ-specific set is used once.

Second, it sells services through the NOP. This gives transplant centers a fuller package: organ retrieval, clinical support, aircraft, and ground logistics. Service revenue can deepen customer ties, but it also brings flight operations, maintenance, hiring, and scheduling risk.

In Q1 2026, product revenue was $108 million and service revenue was $66 million. U.S. transplant revenue was $167 million, while international revenue was $5.6 million, so the business is still mostly U.S. based. Europe is the next major expansion area, but it will likely cost money before it shows whether the U.S. model can travel.

03 Product portfolio

What TransMedics sells

Growth engine

OCS Heart

Warm perfusion system for donor hearts. It is part of the core FDA-approved OCS platform and is central to the company’s transplant growth story.

Steady

OCS Lung

Warm perfusion system for donor lungs. It supports the same model of reusable consoles and single-use organ-specific disposable sets.

Growth engine

OCS Liver

Warm perfusion system for donor livers. Liver and heart case growth have been important drivers of NOP service revenue in recent filings.

Cash cow

Single-use disposable sets

These sets are required for each OCS transplant. They create recurring product revenue each time a center uses the system.

Growth engine

National Organ Program

NOP bundles organ retrieval, clinical support, and transport. It can make adoption easier for transplant centers, but it also makes TransMedics an aviation and logistics operator.

Option

CHOPS

CHOPS is a controlled cold-preservation system aimed at short-transport donor hearts. Management expects FDA activity around the IDE supplement and later 510(k) process to be a key watch item.

Option

OCS Kidney Gen 3.0

Kidney is a future platform launch, not a current major revenue line in the provided filings. If successful, it would add a large new organ category to the OCS model.

04 Business segments

Q1 mix still leans product

Net Product Revenue62%modest

Service Revenue38%growing fast

Segment mix is based on Q1 2026 revenue disclosed in the internal company context: $108 million of product revenue and $66 million of service revenue. Sales remain concentrated in the U.S., with $167 million of U.S. transplant revenue and $5.6 million of international revenue in Q1 2026.

05 Risk factors

What could break the case

Donor volume shock

High impact · Medium odds

TransMedics depends on transplant volume. Management said U.S. deceased donor numbers were below expectations in early 2026 due to friction tied to the Transplant Modernization Act. Fewer donor organs mean fewer OCS cases and less demand for NOP services.

We watchQuarterly U.S. deceased donor volume, OCS case volume, and management comments on OPO behavior.

NOP cost creep

High impact · Medium odds

The NOP can be a moat, but it is complex. Aircraft, pilots, maintenance, dispatch, and clinical support add fixed costs. Q1 2026 net income fell to $7.3 million from $25.7 million a year earlier, showing how fast margin can compress when spending rises.

We watchService gross margin, operating margin, aircraft additions, and cash used for logistics expansion.

Europe rollout stalls

Medium impact · Medium odds

Management wants to replicate the U.S. NOP model in Europe through PAD Aviation. That could expand the market, but Europe has different transplant systems, hospital buying patterns, and flight logistics. Slow adoption would make the upfront spending harder to defend.

We watchInternational revenue growth, European NOP case counts, and updates on PAD Aviation integration.

CHOPS pricing disappoints

Medium impact · Medium odds

CHOPS targets cold static storage, especially short-transport donor hearts. That market may have different pricing and margin than OCS warm perfusion. If CHOPS wins volume but earns low margins, it may add revenue without much profit.

We watchFDA progress, 510(k) clearance timing, launch pricing, and CHOPS gross margin commentary.

OPO bid uncertainty

Medium impact · Medium odds

TransMedics wants to bid for donor service areas linked to decommissioned organ procurement organizations if CMS allows for-profit bidders. This could give the company deeper control of the transplant chain. It could also require large capital outlays and new operating duties.

We watchCMS rules on bidder eligibility, required capital commitments, and any announced DSA bids.

Debt and covenant pressure

Medium impact · Low odds

The 2025 Form 10-K warns that failure to comply with covenants under the CIBC Credit Agreement could accelerate obligations. Debt is not the main story today, but it matters more if margins stay weak or logistics spending keeps rising.

We watchDebt balances, covenant disclosures, interest costs, and free cash flow.

06 Quick answers

In one breath

What does TransMedics do?

TransMedics makes systems that preserve donor organs for transplant. Its OCS platform keeps hearts, lungs, and livers warm and perfused, and its NOP helps move organs from donors to transplant centers.

How does TransMedics make money?

It sells single-use disposable sets used with OCS consoles, and it sells logistics and clinical services through the NOP. In Q1 2026, product revenue was $108 million and service revenue was $66 million.

Why did the TransMedics thesis weaken in 2026?

Growth slowed to 21% year over year in Q1 2026, and net income fell sharply from the prior year. Management is spending heavily on Europe, CHOPS, Gen 3.0 work, and aviation while U.S. donor volumes are under pressure.

What is CHOPS?

CHOPS is TransMedics’ Controlled Hypothermic Organ Preservation System. It is aimed at cold storage use cases, especially short-transport donor hearts, and could expand the company beyond warm perfusion.